CoChat

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index; 5 of the 10 sources its claims cite were checked for support.

Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes

Open access

Abstract

Abstract Background Orforglipron, a novel oral, non-peptide glucagon like peptide-1 (GLP-1) receptor agonist, has demonstrated efficacy in improving body weight reduction and glycemic control. However, its potential benefits in improving cardiovascular (CV) risk factors have yet to be determined. We assessed the effect of orforglipron in participants with type 2 diabetes (T2D) and/or overweight or obesity on blood pressure, lipid, and inflammatory biomarkers associated with risk for major adverse cardiovascular events. Methods Using data from participants with available samples from Phase 2 trials of orforglipron in participants with T2D (N = 361) or with overweight or obesity without diabetes mellitus (N = 234), we performed an exploratory analysis of changes in CV risk markers. For the T2D study, participants mean age 59 years, 40% were assigned female at birth with a mean HbA 1c of 8.1% and mean BMI of 35.3 kg/m 2 ; they received once daily orforglipron doses (3, 12, 24, 36, or 45 mg) or once weekly subcutaneous dulaglutide 1.5 mg, or placebo. In the obesity study, participants had a mean age 54 years, 60% were assigned female at birth, and mean BMI was 37.9 kg/m 2 ; they received once daily orforglipron (12, 24, 36, or 45 mg) or placebo. The change from baseline at 26 weeks (T2D study) or 36 weeks (obesity study) in blood pressure, lipids (cholesterol, triglycerides, Apolipoprotein B (ApoB), Apolipoprotein C3 (ApoC3), N-terminal pro-b-type natriuretic peptide (NT-pro-BNP), and inflammatory biomarkers (high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6)) were assessed. Results Significant placebo-adjusted decreases from baseline in blood pressure, low-density lipoprotein (LDL) cholesterol, triglycerides, ApoB, ApoC3, and hsCRP were observed following orforglipron treatment in participants with T2D and/or overweight or obesity. In both studies, improvements in blood pressure, lipid parameters, and most of the evaluated biomarkers were of similar magnitude after treatment with 12 mg orforglipron as with 24, 36, and 45 mg. Conclusion Orforglipron treatment was associated with beneficial changes in CV risk markers in participants with T2D and in participants with overweight/obesity without T2D. (Clinicaltrials.gov: NCT05048719, NCT05051579). Graphical abstract

Overview

CoChat Summary

TL;DR

In exploratory analyses of two Phase 2 orforglipron trials, treatment was associated with improvements in several cardiovascular risk biomarkers in people with type 2 diabetes and in people with overweight/obesity without diabetes. The main signals were lower blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP, with some effects appearing similar at 12 mg and higher doses.

Key findings

  • In the T2D trial, orforglipron reduced systolic blood pressure by −7.3 to −9.4 mmHg at week 26, versus −5.8 mmHg with placebo; diastolic blood pressure changes were −0.7 to −2.7 mmHg and not significantly different from placebo.
  • In the obesity trial, systolic blood pressure fell by −6.5 to −10.6 mmHg at week 36 versus −1.9 mmHg with placebo, and diastolic blood pressure reductions of −1.8 to −4.3 mmHg were significant for the 12, 36, and 45 mg groups versus placebo.
  • Lipids improved with orforglipron: in T2D, LDL cholesterol decreased by −3.7 to −14.3%, triglycerides by −8.4 to −16.6%, and total cholesterol by −2.1 to −8.0%; in obesity, LDL decreased by −5.8 to −11.8% and triglycerides by −6.7 to −14.6%.
  • Inflammatory/other biomarkers also improved: hsCRP fell by −26.0 to −39.3% in T2D and −27.1 to −41.9% in obesity; ApoB fell by −8.3 to −12.2% in T2D and −11.4 to −13.4% in obesity; ApoC3 fell by −7.2 to −20.9% in T2D and −16.4 to −19.7% in obesity.

Methods

  • Exploratory analysis of biomarker changes using data from two completed Phase 2 randomized multicenter studies of orforglipron: one in T2D and one in overweight/obesity without diabetes.
  • Sample sizes with evaluable biomarker data were 361/383 randomized participants in the T2D study and 234/272 in the obesity study; treatment arms included multiple once-daily orforglipron doses, placebo, and in T2D a once-weekly dulaglutide 1.5 mg comparator.
  • Outcomes were change from baseline in blood pressure, lipids, ApoB, ApoC3, NT-pro-BNP, hsCRP, and IL-6 at 26 weeks (T2D) or 36 weeks (obesity), analyzed with mixed model repeated measures or ANCOVA and compared to placebo at p < 0.05 without multiple-comparison adjustment.

Limitations

  • The paper states the analyses were exploratory, the trials were not specifically designed to assess these biomarker changes, and the findings require further validation through larger, more targeted studies.
  • The paper states that relatively small sample sizes for each treatment group may have contributed to apparent inconsistencies in dose response.
  • Evident from the text: the analysis is limited to biomarkers, so it does not demonstrate cardiovascular outcome benefit; the authors explicitly note that formal comparisons between the T2D and obesity studies were not performed and that cross-trial comparisons should be interpreted with caution.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12933-025-02781-x

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Treatment effects on blood pressure in participants with or without T2D. Data are LSM ± SE (baseline and change at week 26. #p < 0.05, ## p < 0.01, ### p < 0.001 change from baseline. *p < 0.05, **p < 0.01, ***p < 0.001 for OFG vs PBO. Mean change in A systolic blood pressure at week 26 in participants with T2D, B systolic blood pressure at week 36 in participants with obesity, C diastolic blood pressure at week 26 in participants with T2D D diastolic blood pressure at week 36 in participants with obesity
Fig. 1 Treatment effects on blood pressure in participants with or without T2D. Data are LSM ± SE (baseline and change at week 26. #p < 0.05, ## p < 0.01, ### p < 0.001 change from baseline. *p < 0.05, **p < 0.01, ***p < 0.001 for OFG vs PBO. Mean change in A systolic blood pressure at week 26 in participants with T2D, B systolic blood pressure at week 36 in participants with obesity, C diastolic blood pressure at week 26 in participants with T2D D diastolic blood pressure at week 36 in participants with obesityCC BY · PubMed Central
Fig. 2 Treatment effects on lipid parameters in participants with or without T2D. Left (26-week T2D study), Right (36-week obesity study). Data are LSM ± SE (baseline and change at Week 26. #p < 0.05, ## p < 0.01, ### p < 0.001 change from baseline. *p < 0.05, **p < 0.01, ***p < 0.001 for OFG vs PBO. †p < 0.05, ††p < 0.01, †††p < 0.001 for OFG vs dulaglutide A Mean change in total cholesterol from baseline to week 26 in T2D. B Mean change in total cholesterol from baseline to week 36 in obesity. C Mean change in LDL from baseline to week 26 in T2D D Mean change in LDL from baseline to week 36 in obesity. E Mean change in HDL from baseline to week 26 in T2D F Mean change in LDL from baseline to week 36 in obesity. G Mean change in triglycerides from baseline to week 26 in T2D H Mean change in triglycerides from baseline to week 36 in obesity
Fig. 2 Treatment effects on lipid parameters in participants with or without T2D. Left (26-week T2D study), Right (36-week obesity study). Data are LSM ± SE (baseline and change at Week 26. #p < 0.05, ## p < 0.01, ### p < 0.001 change from baseline. *p < 0.05, **p < 0.01, ***p < 0.001 for OFG vs PBO. †p < 0.05, ††p < 0.01, †††p < 0.001 for OFG vs dulaglutide A Mean change in total cholesterol from baseline to week 26 in T2D. B Mean change in total cholesterol from baseline to week 36 in obesity. C Mean change in LDL from baseline to week 26 in T2D D Mean change in LDL from baseline to week 36 in obesity. E Mean change in HDL from baseline to week 26 in T2D F Mean change in LDL from baseline to week 36 in obesity. G Mean change in triglycerides from baseline to week 26 in T2D H Mean change in triglycerides from baseline to week 36 in obesityCC BY · PubMed Central
Fig. 3 Treatment effects on apolipoproteins in participants with or without T2D. Data are LSM ± SE (baseline and change at week 26. #p < 0.05, ## p < 0.01, ### p < 0.001 change from baseline. *p < 0.05, **p < 0.01, ***p < 0.001 for OFG vs PBO. †p < 0.05, ††p < 0.01, †††p < 0.001 for OFG vs dulaglutide. A Mean change in ApoB from baseline to week 26 in T2D. B Mean change in ApoB from baseline to week 36 in obesity. C Mean change in ApoC3 from baseline to week 26 in T2D D Mean change in ApoC3 from baseline to week 36 in obesity
Fig. 3 Treatment effects on apolipoproteins in participants with or without T2D. Data are LSM ± SE (baseline and change at week 26. #p < 0.05, ## p < 0.01, ### p < 0.001 change from baseline. *p < 0.05, **p < 0.01, ***p < 0.001 for OFG vs PBO. †p < 0.05, ††p < 0.01, †††p < 0.001 for OFG vs dulaglutide. A Mean change in ApoB from baseline to week 26 in T2D. B Mean change in ApoB from baseline to week 36 in obesity. C Mean change in ApoC3 from baseline to week 26 in T2D D Mean change in ApoC3 from baseline to week 36 in obesityCC BY · PubMed Central
Fig. 4 Treatment effects on hsCRP, IL-6 and NT-pro-BNP in participants with or without T2D. Data are LSM ± SE (baseline and change at week 26. #p < 0.05, ## p < 0.01, ### p < 0.001 change from baseline. *p < 0.05, **p < 0.01, ***p < 0.001 for OFG vs PBO. †p < 0.05, ††p < 0.01, †††p < 0.001 for OFG vs dulaglutide. A Mean change in high-sensitivity C reactive protein (hsCRP) at week 26 in T2D. B Mean change in high-sensitivity C reactive protein(hsCRP) at week 36 in obesity. C Mean change in Interleukin-6 at week 26 in T2D. D Mean change in Interleukin-6 at week 36 in obesity. (E)Mean change in NT-ProBNP at week 26 in T2D. F Mean change in NT-ProBNP at week 36 in obesity
Fig. 4 Treatment effects on hsCRP, IL-6 and NT-pro-BNP in participants with or without T2D. Data are LSM ± SE (baseline and change at week 26. #p < 0.05, ## p < 0.01, ### p < 0.001 change from baseline. *p < 0.05, **p < 0.01, ***p < 0.001 for OFG vs PBO. †p < 0.05, ††p < 0.01, †††p < 0.001 for OFG vs dulaglutide. A Mean change in high-sensitivity C reactive protein (hsCRP) at week 26 in T2D. B Mean change in high-sensitivity C reactive protein(hsCRP) at week 36 in obesity. C Mean change in Interleukin-6 at week 26 in T2D. D Mean change in Interleukin-6 at week 36 in obesity. (E)Mean change in NT-ProBNP at week 26 in T2D. F Mean change in NT-ProBNP at week 36 in obesityCC BY · PubMed Central

Verification

Claims the paper makes

3 Valid · 0 Not valid · 3 Not checked · 30 Own results and interpretations

6 more claims

Create a free account to see all 36 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 17
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 43 references

Cited by

See all 26

Metadata

Authors
Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K.
Affiliations
  • York University (CA)
  • Velocity Clinical Research (United States) (US)
  • Eli Lilly (United States) (US)
Corresponding author
Wharton, Sean
Venue
Cardiovascular Diabetology
Published
2025-06-06
Volume
24
Issue
1
Pages
240-240
ISSN
1475-2840 (ISSN-L)
OpenAlex
W4411100032
Cited by
26
References
43
Citations by year
2026: 20 · 2025: 6
FWCI
17.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
orforglipron, GLP-1 receptor agonists, type 2 diabetes, obesity, overweight, cardiovascular risk markers, blood pressure, lipid profile, LDL cholesterol, triglycerides, apolipoprotein B, apolipoprotein C-III, NT-proBNP, high-sensitivity C-reactive protein, interleukin-6, dulaglutide, major adverse cardiovascular events
MeSH terms
Glucagon-Like Peptide-1 Receptor, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Aged, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Lipids, Male, Middle Aged, Obesity, Oxadiazoles, Time Factors, Biomarkers, Treatment Outcome, Fluorine Compounds, Risk Assessment, Inflammation Mediators, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. https://app.cochat.ai/papers/10.1186/s12933-025-02781-x
The paper
Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025). Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-025-02781-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.